by Entry of Novel Technologies Coupled With Increasing Focus on R&D to Bolster Market Growth
The significant rise in the number of individuals that are affected by epidermolysis bullosa (EB) is one of the primary factors that is expected to drive the global dystrophic epidermolysis bullosa treatment market in the upcoming years. At present, dystrophic epidermolysis bullosa is the second most common type of epidermolysis bullosa and as per current observations, the number of cases is likely to grow at a consistent pace in the upcoming years. Thus, the demand for dystrophic epidermolysis bullosa treatment is on the rise.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111834
Advancements in science and increasing focus on R&D activities are likely to provide an impetus to the overall development of the global dystrophic epidermolysis bullosa treatment market during the forecast period. The entry of whole-exome sequencing has revolutionized dystrophic epidermolysis bullosa diagnostics and treatment due to the development of gene panels across various epidermolysis bullosa treatment centers. This, in turn, has accelerated diagnosis and prognostication. In addition, due to the strides taken by gene editing, gene editing-based therapies are gaining immense popularity particularly for targeted treatment. At present, researchers involved in the current dystrophic epidermolysis bullosa treatment market are increasingly focusing on gaining a better understanding of the overall pathogenic mechanism of various subtypes of epidermolysis bullosa treatment, including dystrophic epidermolysis bullosa treatment.
At the back of these factors, the global dystrophic epidermolysis bullosa treatment market is on course to attain a market value of ~US$ 710 Mn by the end of 2030.
Advent of New Treatment Modalities to Drive Global Market
The increasing prevalence of epidermolysis bullosa– a set of hereditary skin blistering diseases has prompted researchers and scientists to seek newer treatment modalities – a factor that is expected to drive the global dystrophic epidermolysis bullosa treatment market during the assessment period. Furthermore, as researchers have gained immense knowledge pertaining to the genetic mutation of dystrophic epidermolysis bullosa, newer treatment modalities are currently making inroads into the global dystrophic epidermolysis bullosa treatment market. The increasing understanding of disease etio-pathogenesis is a top factor that is accelerating the development of new and cutting-edge therapy alternatives. In the current scenario, cell-based and first gene therapies are increasingly being tested in clinical trials and at the preclinical level. Moreover, the increasing knowledge of various secondary disease mechanisms has paved the way for clinical testing and development of symptom-relief therapies, including dystrophic epidermolysis bullosa treatment– a major factor that is anticipated to fuel the growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period.
Strides Taken by Gene Therapy and Tissue Engineering to Fuel Adoption
Due to the notable progress made by gene therapy and tissue engineering, dystrophic epidermolysis bullosa treatment has improved by a considerable margin. Moreover, apart from these alternatives, stem cell transplantation and gene correction are some of the other treatment alternatives that are likely to gain adoption in the global dystrophic epidermolysis bullosa treatment market during the assessment period. A number of research and development activities has indicated that in vitro gene therapy of keratinocyte stem cells and transplanting the same into the skin is one of the most promising and novel treatments that is likely to gain considerable adoption in the upcoming years. Scientists and stakeholders operating in the current dystrophic epidermolysis bullosa treatment market landscape are also focusing on enhancing the clinical features in epidermolysis bullosa patients by relying on in vitro gene therapy of stem cell keratinocytes– a factor that is projected to boost the global dystrophic epidermolysis bullosa treatment market during the assessment period.
Research and Development Activities in Full Swing amid COVID-19 Pandemic
The COVID-19 pandemic is expected to have a moderate impact on the overall growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period. Research and development activities for dystrophic epidermolysis bullosa treatment are underway to identify the potential threat of the novel SARS-CoV-2 virus to patients suffering from dystrophic epidermolysis bullosa. Several studies have revealed that patients suffering from epidermolysis bullosa, particularly with syndromic forms are at a higher risk of acquiring the novel COVID-19 infection.
Overall, the outbreak of the COVID-19 pandemic is expected to accelerate research and development activities, thereby opening new avenues.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Dystrophic Epidermolysis Bullosa Treatment Market
Analysts’ Viewpoint
The global dystrophic epidermolysis bullosa treatment market is expected to expand at a CAGR of ~5% during the forecast period. The market growth can be primarily attributed to increasing prevalence of epidermolysis bullosa worldwide, strides taken by gene editing, tissue engineering and stem cell technology, and rising investment for research and development. Market players are projected to focus on research and development and create awareness related to dystrophic epidermolysis bullosa treatment to gain a competitive edge.
Dystrophic Epidermolysis Bullosa Treatment Market: Overview
The global dystrophic epidermolysis bullosa treatment market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of dystrophic epidermolysis bullosa and surge in research for managing dystrophic epidermolysis bullosa are projected to drive the global dystrophic epidermolysis bullosa treatment market during the forecast period
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued at over US$ 412 Mn in 2019 and is anticipated to expand at a CAGR of ~5% from 2020 to 2030
Rise in Prevalence of Dystrophic Epidermolysis Bullosa to Drive Demand for Dystrophic Epidermolysis Bullosa Treatment: Key Driver
According to the European Union, dystrophic epidermolysis bullosa is defined as a rare disease, with a prevalence of no more than 50 people per 100,000 population, whereas in the U.S., rare disease is defined as condition which affects fewer than 200,000 individuals
According to the National EB Registry, the overall prevalence of EB is 11.07 per one million live births. The prevalence of dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB) is 1.49 and 1.35 per 1 million live births, respectively.
Data on pregnancy and EB are limited; however, a recent survey did not detect increased risk for pregnancy-related complications in women with EB
According to Orphanet, dystrophic epidermolysis bullosa is the second most common form of EB-epidermolysis bullosa, the first being EB simplex. The overall reported prevalence varies from 1/49,000 inhabitants in Scotland to 1/420,168 in the U.S.
According to the United States National Epidermolysis Bullosa Registry, the overall incidence and prevalence of epidermolysis bullosa is 19.6 and 11.07 cases per 1 million live births, respectively. The incidence and prevalence of epidermolysis bullosa simplex were 7.87 and 6 cases per 1 million live births, respectively.
According to the National Epidermolysis Bullosa Registry, the prevalence of epidermolysis bullosa in Norway is 54 cases per million live births, 7.8 cases per million live births in Japan, 15.4 cases per million live births in Italy, 10.3 cases per million live births in Australia, and 9.6 cases per million live births in Croatia
According to Springer Nature Limited (2003), the prevalence of all types of EB is estimated at 19 per million in the U.S. and the prevalence of dystrophic form of EB is 2.4 per million live births in the country
Surge in Research for Managing Dystrophic Epidermolysis Bullosa to Boost Market Growth
Demand for the development of newer and technologically enhanced products such as biologics and biosimilars is rising globally, owing to the treatment efficiency of these drugs. Hence, major players operating in the market invest in research to develop new drugs.
Rise in investment in research & development programs by key players is likely to propel the market during the forecast period
According to the Journal of Investigative Dermatology, the development of molecular therapies for epidermolysis bullosa is going on which addresses directly the molecular defects that lead to skin fragility, which manifests clinically as blisters and erosions. Complementary technologies, primarily in the advanced stages of preclinical research or already in early-stage clinical trials, have been reported.
According to the Journal of Investigative Dermatology, few researches being carried out on recessive dystrophic epidermolysis bullosa (RDEB) include grafting of genetically modified epidermal keratinocytes, localized injection of allogeneic fibroblasts into the skin, application of chimeric skin equivalents (fibroblasts from healthy donors and patient keratinocytes), allogeneic bone marrow transplantation (standard procedures), bone marrow transplantation with reduced intensity conditioning, and protein replacement by intradermal injection (type VII collagen)
Withdrawal of Drugs to Hamper Market
According to Physiopedia, the use of topical opiates for pain management has been proven to reduce the need of powerful systemic analgesia. Amitriptyline has also been found to be useful in both children and adults in reducing pain. For systemic treatment, no agents so far have proven to be effective in controlling blisters in patients diagnosed with EB.
No other medication, including phenytoin and tetracycline, have improved the blistering or epithelial disadhesion in EB. Hence, presently, there is no reliable clinical trial evidence for any type of treatment with medication.
In September 2017, Rival Amicus Therapeutics withdrew its AP101 drug, which was in phase III clinical study. AP101 drug was a water-based cream, which is only supposed to be applied when dressings are changed every three or four days, as recommended for EB patients. The cream was water-based and therefore a patient needed to change the dressing very frequently and failed to hit targets for wound closure in patients.
These factors are likely to restrain the market during the forecast period
Dystrophic Epidermolysis Bullosa Treatment Market: Competition Landscape
This report profiles major players in the global dystrophic epidermolysis bullosa treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
Leading players operating in the global dystrophic epidermolysis bullosa treatment market are
- Krystal Biotech
- Castle Creek Biosciences, Inc.
- Abeona Therapeutics, Inc.
- Amryt Pharma plc
- Wings Therapeutics
- Phoenix Tissue Repair
- InMed Pharmaceuticals, Inc.
- RegeneRx
- Holostem Terapie Avanzate S.r.l.
Key Questions Answered in Dystrophic Epidermolysis Bullosa Treatment Market Report
- What is the scope of growth of companies present in the global dystrophic epidermolysis bullosa treatment market?
- What will be the Y-o-Y growth of the global dystrophic epidermolysis bullosa treatment market between 2020 and 2030?
- What is the influence of changing trends in technologies on the global dystrophic epidermolysis bullosa treatment market?
- Will North America continue to be the most profitable market for dystrophic epidermolysis bullosa treatment providers?
- Which factors are anticipated to hamper the growth of the global dystrophic epidermolysis bullosa treatment market during the forecast period?
- Which are the leading companies in the global dystrophic epidermolysis bullosa treatment market?
Dystrophic Epidermolysis Bullosa Treatment Market – Segmentation
Treatment Type
- Antibiotics
- Corticosteroids
- Opioid Analgesics
- Anticonvulsant
- Others
Disease Type
- Dominant Dystrophic Epidermolysis Bullosa (DDEB)
- Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111834/2900
